Roche ramps up fast-growing infectious Dx segment with $1.8B takeout of GenMark

Roche is adding another diagnostics platform for infectious diseases to what has been its best performing business in the past year. 

On the back of Roche’s build-out of its SARS-CoV-2 testing franchise, the Swiss pharma is adding to its infectious diseases diagnostics portfolio with the $1.8 billion acquisition of GenMark Diagnostics Inc. (NASDAQ:GNMK). The Southern California company markets the ePLEX system along with molecular diagnostic panels to detect multiple pathogens from a single patient sample. The panels cover respiratory pathogens, including variants of SARS-CoV-2, and blood-borne pathogens...